Vericel (VCEL) Other financing activities (2010 - 2026)
Vericel (VCEL) posted Other financing activities of -$23000.0 for Q2 2026, down 9.52% sequentially from -$21000.0 in Q1 2026, and down 109.09% YoY from $253000.0 in Q2 2025.
Powered by 
Analysis
Vericel (VCEL) Other financing activities (2010 - 2026) Analysis & Trends
Vericel has reported Other financing activities for 10 years, with the latest figure at -$23000.0 in Q2 2026.
- Quarterly Other financing activities fell 109.09% year-over-year to -$23000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$76000.0 (down 406.67% YoY) and the FY2025 annual result came in at -$47000.0, changed N/A from the prior year.
- Other financing activities slipped to -$23000.0 in Q2 2026 per VCEL's latest filing, from -$21000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $3.7 million in Q4 2022 and troughed at -$23000.0 in Q2 2026.
- A 4-year average of $270769.2 and a median of -$19000.0 in 2022 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2022 and 2026: Other financing activities jumped 148.89% in 2022, then slumped 425.0% in 2026.
- Over 4 years, Other financing activities stood at $3.7 million in 2022, then plunged by 100.57% to -$21000.0 in 2023, then changed by 0.0% to -$21000.0 in 2025, then fell by 9.52% to -$23000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered -$23000.0, -$21000.0, and -$21000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -23,000.00 |
| Mar 31, 2026 | -21,000.00 |
| Dec 31, 2025 | -21,000.00 |
| Sep 30, 2025 | -11,000.00 |
| Jun 30, 2025 | -11,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Sep 30, 2023 | -21,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Mar 31, 2023 | -21,000.00 |
| Dec 31, 2022 | 3.69 Mn |
| Sep 30, 2022 | -21,000.00 |
| Jun 30, 2022 | 1,000.00 |
| Mar 31, 2022 | -19,000.00 |
| Dec 31, 2021 | 1.48 Mn |
| Sep 30, 2021 | 2.08 Mn |
| Jun 30, 2021 | 3.84 Mn |
| Mar 31, 2021 | 3.78 Mn |
| Dec 31, 2020 | 4.45 Mn |
| Sep 30, 2020 | 809,000.00 |
| Jun 30, 2020 | 953,000.00 |